Author

B. Tessier-Cloutier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

D. G. Huntsman· 2 shared A. Albert· 1 shared A. Cheng· 1 shared A. Lum· 1 shared A. N. Karnezis· 1 shared B. C. Gilks· 1 shared B. E. Weissman· 1 shared C. B. Gilks· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. G. Huntsman

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type

J. X. Ji, D. R. Cochrane, B. Tessier-Cloutier, S. Chen, G. Ho, K. V. Pathak, I. Alcazar, D. Farnell, S. Leung, A. Cheng, C. Chow, S. Colborne, G. Luca Negri, F. Kommoss, A. N. Karnezis, , D. G. Huntsman

This paper identifies ASS1 deficiency in rare ovarian cancers and shows that ADI-PEG20 inhibits tumor growth in ASS1-deficient models.

bioRxiv · Nov 17, 2019 · PreprintCancer Biology

Oncogenic Mutations in Histologically Normal Endometrium: The New Normal?

V. Lac, T. M. Nazeran, B. Tessier-Cloutier, R. Aguirre-Hernandez, A. Albert, A. Lum, J. Khattra, T. Praetorius, M. Mason, D. Chiu, M. Köbel, P. J. Yong, B. C. Gilks, M. S. Anglesio, D. G. Huntsman

This study finds that over 50% of histologically normal endometrium samples contain somatic driver mutations, including KRAS, PIK3CA, FGFR2, and PTEN loss, with prevalence increasing with age.

bioRxiv · Feb 26, 2019Pathology